Mipharm S.p.A. was born in January 1998 following the merger of Sandoz
and Ciba Geigy, from which resulted the new company Novartis. Mipharm was
founded by a group of ex managers coming from Novartis by mean of a spin-off of
the manufacturing site located in Milan, Via Quaranta, previously owned by Sandoz.
In December 2016, Mandarin Capital Partners II acquired the majority
stake in Mipharm share capital.
Today, Mipharm is one of the most valuable third party manufacturing and
new product development sites in Italy and it claims to have four FDA approvals
(Nasal Spray Solution, Oral Potent Drug, Sachet, Packaging).
Mipharm has been investing significant resources to continuously improve
manufacturing site qualitative standard and currently it is able to produce and
to pack a huge range of products and pharmaceutical forms.